WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Affinity Health RSA
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Webinar
Industrial Impact
Gator Bio | September 15, 2021
Gator Bio, Inc. announced today the launch of the GatorPlus, a next generation biolayer interferometry (BLI) instrument and two new biosensor products, Gator™ Flex SA Kit and Gator™ AAVX probe. The GatorPlus adds to the currently available GatorPrime instrument; and the new Gator™ Flex SA Kit and Gator™ AAVX probe expand the off the shelf biosensor portfolio to 14 products for the North America market. Gator Bio also offers on demand custom biosensors for specific applica...
Medical
Verona Pharma | November 19, 2020
A British clinical-stage biotech firm with U.S. base camp in Raleigh is investigating the alternative of repurposing its leading drug candidate to treat COVID-19 patients. Flush with $200 million after a July raise, the London-based Verona Pharma is now making large walks with its "first-in-class" drug, ensifentrine, targeting chronic obstructive pulmonary disease (COPD). Now, against the backdrop of a pandemic, it’s pushing ahead with a pilot clinic...
BioSpace | March 24, 2020
Axim Biotech® Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that its subsidiary Sapphire Biotech, Inc. (“Sapphire”) has completed pre-clinical drug studies on a new compound, SPX-1009, demonstrating 10 times greater potency than its parent compound, SBI-183, in inhibiting metastasis....
Labiotech | January 15, 2020
The US company bluebird bio has launched the first gene therapy for the blood disorder transfusion-dependent beta thalassemia in the EU, with a hospital in Germany becoming its first qualified treatment center. Bluebird bio’s gene therapy, branded as Zynteglo, was given conditional market approval by the EU in June 2019. It was the first gene therapy approved to treat people over 12 years of age with all but the most severe form of transfusion-dependent beta thalassemia, a condition that n...
MedTech
Video
Whitepaper
Medical, Industry Outlook
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE